Literature DB >> 52423

The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

P J Lachmann, L Halbwachs.   

Abstract

Minor elevation of the concentration of the C3b inactivator (KAF) in whole serum (by 15-25%) markedly inhibits the capacity of the serum to support complement activation by inulin, aggregated IgG and by low concentrations of CVF. However, there was no effect when large concentrations of CVF were used nor was the spontaneous ageing of C3 slowed by increased KAF concentrations. These findings show that the activity of the C3b feedback cycle can be reduced by raising the KAF concentration above physiological levels. This finding may provide a mechanism for damping down complement activation locally in vivo. It seems that the spontaneous ageing of C3 in vitro does not involve a KAF-inhibitable step and therefore cannot be involved to explain the 'C3 tickover' in vitro.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 52423      PMCID: PMC1538241     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  Reaction mechanism of the alternative pathway of complement fixation.

Authors:  P J Lachmann; P Nicol
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

3.  Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.

Authors:  A Nicholson; V Brade; G D Lee; H S Shin; M M Mayer
Journal:  J Immunol       Date:  1974-03       Impact factor: 5.422

4.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

5.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  Further studies on the C3b inactivator or conglutinogen activating factor (KAF).

Authors:  P J Lachmann; P Nicol; W P Aston
Journal:  Immunochemistry       Date:  1973-10

7.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

8.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

9.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

  10 in total
  44 in total

Review 1.  Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.

Authors:  Tolulase Olutogun; Ilaria Cutini; Rosario Notaro; Lucio Luzzatto
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443

2.  Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.

Authors:  A K Cheung; C J Parker; L Wilcox
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Properdin binding to complement activating surfaces depends on initial C3b deposition.

Authors:  Morten Harboe; Christina Johnson; Stig Nymo; Karin Ekholt; Camilla Schjalm; Julie K Lindstad; Anne Pharo; Bernt Christian Hellerud; Kristina Nilsson Ekdahl; Tom Eirik Mollnes; Per H Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

4.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

5.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

Review 6.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

Review 7.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

Review 8.  The quest for an intrinsic C3 activating factor in human glomerular disease.

Authors:  J L Roberts; E J Lewis
Journal:  Surv Immunol Res       Date:  1982

9.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

10.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.